Compare Gilead Sciences, Inc. (GILD) vs iShares Core S&P 500 ETF (IVV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs iShares Core S&P 500 ETF — how do they compare? Gilead Sciences, Inc. trades at $151.17 (market cap $182.40B), while iShares Core S&P 500 ETF trades at $781.97 (market cap $897.20B). The key difference: iShares Core S&P 500 ETF is far larger — about 4.9× Gilead Sciences, Inc.'s market cap, and Gilead Sciences, Inc. pays a 2.23% dividend while iShares Core S&P 500 ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Gilead Sciences, Inc. for 111 Days and iShares Core S&P 500 ETF for 46 Days on average.
| GILD | IVV | |
|---|---|---|
Market Cap | $182.40B | $897.20B |
Volume | 4,469,821 | 4,580,672 |
Sector | Health | Broad Market / Factor |
52-Week High | $155.80 | $782.58 |
52-Week Low | $117.18 | $634.93 |
Typical Hold Time | 111 Days | 46 Days |
Enterprise Value | $205.46B | — |
Dividend Yield | 2.23% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $147.10, showing modest daily gains of 0.17% with strong technical support at $145. The company demonstrates robust fundamentals with Q2 2026 earnings beating expectations despite a net loss, while maintaining a high gross margin of 79.59%. Recent developments include expanded HIV prevention drug access across Latin America through a PAHO partnership, positioning the company for growth in key therapeutic areas.
GILD presents a mixed outlook with strong analyst support (65.5% buy ratings) and a $151.57 price target offering 3% upside, but faces headwinds from negative net income margins and elevated debt levels. The stock's valuation appears reasonable with a P/E of 17.84, though investors should monitor the company's ability to translate top-line strength into sustainable profitability amid competitive pressures.
IVV, tracking the S&P 500, trades at $777.38, down 0.41% on the day, with a bullish technical signal from moving averages and neutral oscillators. Support lies at $775 and resistance at $780. Recent news highlights strong 2026 earnings growth expectations of 35% but a projected slowdown to 15% in 2027, with valuation debates ongoing amid index concentration risks.
The outlook remains cautiously optimistic given bullish technicals and Wall Street's long-term growth projections, but risks include profit growth deceleration, high market concentration, and interest rate sensitivity. IVV offers broad market exposure, yet investors should weigh slowing corporate earnings against historical bullish seasonal trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About iShares Core S&P 500 ETF
IVV tracks the performance of the S&P 500 Index, offering low-cost exposure to 500 of the largest US companies. It is a cornerstone for long-term investors seeking broad growth in the US stock market.
Read more on IVV →
